Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
The primary endpoint in this trial, the difference in time to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28 among PAXLOVID versus placebo recipients, was not met
It identifies the subset of patients who truly benefit from supplementation
When a product goes from Rs 13,000 to Rs 1,300, prescribing and patient usage patterns shift overnight
Article 1 mins Industry Insights Business risks impact industries in different ways
US$ 28.48
US$ 24.05
US$ 26.02
US$ 21.62
